Neurizon Therapeutics (FRA:ECQ0) YoY Rev. per Sh. Growth: 0.00% (As of Dec. 2025)


What is Neurizon Therapeutics YoY Rev. per Sh. Growth?

Neurizon Therapeutics FRA:ECQ0 -3.64% YoY Rev. per Sh. Growth is 0.00% as of Dec. 2025. The stock has 2 warning signs investors should review.

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Neurizon Therapeutics's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2025 was 0.00%.

Neurizon Therapeutics's Revenue per Share for the six months ended in Dec. 2025 was €0.00.

Neurizon Therapeutics YoY Rev. per Sh. Growth Related Terms

Neurizon Therapeutics YoY Rev. per Sh. Growth Historical Data

* Premium members only.

The historical data trend for Neurizon Therapeutics's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurizon Therapeutics YoY Rev. per Sh. Growth Chart

Neurizon Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -42.86 75.00 -28.57 -100.00 0.00

Neurizon Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -100.00 -100.00 0.00 0.00 0.00

Neurizon Therapeutics YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Neurizon Therapeutics's YoY Rev. per Sh. Growth for the fiscal year that ended in Jun. 2025 is calculated as:

YoY Rev. per Sh. Growth (A: Jun. 2025 )
=(Revenue per Share (A: Jun. 2025 )-Revenue per Share (A: Jun. 2024 ))/ | Revenue per Share (A: Jun. 2024 ) |
=(0-0)/ | 0 |
=N/A %

Neurizon Therapeutics's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY Rev. per Sh. Growth (Q: Dec. 2025 )
=(Revenue per Share (Q: Dec. 2025 )-Revenue per Share (Q: Dec. 2024 )) / | Revenue per Share (Q: Dec. 2024 )) |
=(0-0)/ | 0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a YoY Rev. per Sh. Growth of 0.00% mean?
Neurizon Therapeutics (FRA:ECQ0) has a YoY Rev. per Sh. Growth of 0.00% as of Dec. 2025. YoY Rev. per Sh. Growth is the percentage change of revenue per share over the past 12-month. View historical data for Neurizon Therapeutics and its competitors.
Is Neurizon Therapeutics' YoY Rev. per Sh. Growth too high?
Neurizon Therapeutics' current YoY Rev. per Sh. Growth is 0.00%.
How does Neurizon Therapeutics' YoY Rev. per Sh. Growth compare to VRTX and REGN?
Neurizon Therapeutics' YoY Rev. per Sh. Growth of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY Rev. per Sh. Growth for a Biotechnology company?
A good YoY Rev. per Sh. Growth depends on the Biotechnology industry context. However, YoY Rev. per Sh. Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY Rev. per Sh. Growth mean?
A high YoY Rev. per Sh. Growth can signal that a stock is expensive relative to its fundamentals. YoY Rev. per Sh. Growth is the percentage change of revenue per share over the past 12-month. View historical data for Neurizon Therapeutics and its competitors. Neurizon Therapeutics's current YoY Rev. per Sh. Growth is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurizon Therapeutics stock overvalued right now?
Neurizon Therapeutics (FRA:ECQ0) has a current YoY Rev. per Sh. Growth of 0.00%. The current YoY Rev. per Sh. Growth is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY Rev. per Sh. Growth calculated?
YoY Rev. per Sh. Growth is calculated from a company's financial statements. For Neurizon Therapeutics (FRA:ECQ0), the current YoY Rev. per Sh. Growth is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurizon Therapeutics Business Description

Other Exchanges ECQ0:GermanyNUZ:Australia
Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3205
Neurizon Therapeutics Ltd is a clinical-stage biotech company that develops drug discovery intellectual property for the treatment of different types of neurodegenerative diseases. Its product pipeline is NUZ-001 (S-Monepantel).